{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-346857","form_type":"8-K","ticker":"ATRA","cik":"0001604464","company_name":"Atara Biotherapeutics, Inc.","filed_at":"2026-08-12T20:10:20+00:00","discovered_at":"2026-08-12T20:11:00.291705+00:00","generated_at":"2026-08-12T20:11:13.398912+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Atara Q2 net loss $4.8M; FDA meeting backs tab-cel BLA resubmission","bullets":["Q2 2026 net loss of $4.8M ($0.32/share) vs net income of $2.4M in Q2 2025.","Total revenues $0.6M vs $17.6M YoY, down $17.0M on deferred revenue acceleration.","Cash and short-term investments $9.9M at June 30, 2026; operating expenses down 87% YoY.","Cash runway into mid-2027; productive Type A FDA meeting supports tab-cel BLA resubmission.","Eligible for $31M milestone on FDA approval plus tiered royalties on EBVALLO sales."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-346857","json":"https://secwatch.observer/filing/0001193125-26-346857.json","markdown":"https://secwatch.observer/filing/0001193125-26-346857.md","text":"https://secwatch.observer/filing/0001193125-26-346857.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604464/000119312526346857/0001193125-26-346857-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604464/000119312526346857/atra-20260812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-12T20:11:13.398912+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}